Eye Disease

While basking in the glow of the approval for its Alzheimer’s treatment, Biogen Inc (NASDAQ: BIIB) announced that a gene therapy candidate for eye disease failed a late-stage clinical trial, yet again. The company announced topline results from Phase 3 STAR study of...

Shares of Clearside Biomedical Inc (NASDAQ: CLSD), a biopharmaceutical company that focuses on the treatment of serious eye diseases, plunged 60 percent Monday after announcing disappointing results from a Phase 3 study. What Happened Clearside said in a press release its Phase 3 clinical...

Despite a more than 20 percent plunge in Ocular Therapeutix Inc (NASDAQ: OCUL)'s stock Wednesday morning, analysts at Cantor Fitzgerald continue to see tremendous upside in the stock. Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Ocular's stock but with a price...

Shares of Ocular Therapeutix Inc (NASDAQ: OCUL) were trading lower by more than 30 percent heading into Wednesday's open after the biopharmaceutical company confirmed a major setback for its eye drug Dextenza, a therapy used for the treatment of ocular pain following ophthalmic surgery. Ocular...